Today, there are three different drug companies, Amgen, Eli Lilly and Company and Teva Pharmaceuticals scheduled to report the results of studies on a new class of drugs specifically for migraines that appear to be effective but have minimal side effects and work by reducing levels of something known as calcitonin gene-related peptide in the body which is a key driver of migraine pain.
“The current standard of care is that there is no specific migraine preventive treatment at all,” said Dr. Peter J. Goadsby, chair of the scientific programs of the American Headache Society’s annual meeting. “The big problem is that not only do they limited efficacy but they are poorly tolerated.”
“The potential of these new compounds is enormous, and gives us hope that effective specific treatments for migraine may be on the near horizon,” Dr. Goadsby said. “The development of CGRP antibodies offers the simple, yet elegant and long awaited option for migraine patients to be finally be treated with migraine preventives; it’s a truly landmark development.”
The Washington Post
June 17, 2015